Literature DB >> 23006746

The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas aeruginosa independently of ParRS.

Lucía Fernández1, Håvard Jenssen, Manjeet Bains, Irith Wiegand, W James Gooderham, Robert E W Hancock.   

Abstract

Cationic antimicrobial peptides pass across the outer membrane by interacting with negatively charged lipopolysaccharide (LPS), leading to outer membrane permeabilization in a process termed self-promoted uptake. Resistance can be mediated by the addition of positively charged arabinosamine through the action of the arnBCADTEF operon. We recently described a series of two-component regulators that lead to the activation of the arn operon after recognizing environmental signals, including low-Mg(2+) (PhoPQ, PmrAB) or cationic (ParRS) peptides. However, some peptides did not activate the arn operon through ParRS. Here, we report the identification of a new two-component system, CprRS, which, upon exposure to a wide range of antimicrobial peptides, triggered the expression of the LPS modification operon. Thus, mutations in the cprRS operon blocked the induction of the arn operon in response to several antimicrobial peptides independently of ParRS but did not affect the response to low Mg(2+). Distinct patterns of arn induction were identified. Thus, the responses to polymyxins were abrogated by either parR or cprR mutations, while responses to other peptides, including indolicidin, showed differential dependency on the CprRS and ParRS systems in a concentration-dependent manner. It was further demonstrated that, following exposure to inducing antimicrobial peptides, cprRS mutants did not become adaptively resistant to polymyxins as was observed for wild-type cells. Our microarray studies demonstrated that the CprRS system controlled a quite modest regulon, indicating that it was quite specific to adaptive peptide resistance. These findings provide greater insight into the complex regulation of LPS modification in Pseudomonas aeruginosa, which involves the participation of at least 4 two-component systems.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23006746      PMCID: PMC3497197          DOI: 10.1128/AAC.01530-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

Review 2.  Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist.

Authors:  J B Lyczak; C L Cannon; G B Pier
Journal:  Microbes Infect       Date:  2000-07       Impact factor: 2.700

Review 3.  Pseudomonas aeruginosa: all roads lead to resistance.

Authors:  Elena B M Breidenstein; César de la Fuente-Núñez; Robert E W Hancock
Journal:  Trends Microbiol       Date:  2011-06-12       Impact factor: 17.079

Review 4.  Creeping baselines and adaptive resistance to antibiotics.

Authors:  Lucía Fernández; Elena B M Breidenstein; Robert E W Hancock
Journal:  Drug Resist Updat       Date:  2011-02-01       Impact factor: 18.500

5.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

6.  PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance.

Authors:  E L Macfarlane; A Kwasnicka; M M Ochs; R E Hancock
Journal:  Mol Microbiol       Date:  1999-10       Impact factor: 3.501

7.  Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria.

Authors:  C L Friedrich; D Moyles; T J Beveridge; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa.

Authors:  Cédric Muller; Patrick Plésiat; Katy Jeannot
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

9.  Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.

Authors:  Joseph B McPhee; Shawn Lewenza; Robert E W Hancock
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

10.  Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment.

Authors:  Anastasia Nijnik; Laurence Madera; Shuhua Ma; Matthew Waldbrook; Melissa R Elliott; Donna M Easton; Matthew L Mayer; Sarah C Mullaly; Jason Kindrachuk; Håvard Jenssen; Robert E W Hancock
Journal:  J Immunol       Date:  2010-01-27       Impact factor: 5.422

View more
  60 in total

1.  Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture.

Authors:  Bianca Dößelmann; Matthias Willmann; Matthias Steglich; Boyke Bunk; Ulrich Nübel; Silke Peter; Richard A Neher
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Extracellular zinc induces phosphoethanolamine addition to Pseudomonas aeruginosa lipid A via the ColRS two-component system.

Authors:  Emily M Nowicki; John P O'Brien; Jennifer S Brodbelt; M Stephen Trent
Journal:  Mol Microbiol       Date:  2015-05-09       Impact factor: 3.501

3.  Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.

Authors:  C A Colque; A G Albarracín Orio; S Feliziani; R L Marvig; A R Tobares; H K Johansen; S Molin; A M Smania
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 4.  Roles of two-component regulatory systems in antibiotic resistance.

Authors:  Aimee Rp Tierney; Philip N Rather
Journal:  Future Microbiol       Date:  2019-05-08       Impact factor: 3.165

5.  Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing Pseudomonas aeruginosa.

Authors:  Mathias Müsken; Vinay Pawar; Timo Schwebs; Heike Bähre; Sebastian Felgner; Siegfried Weiss; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 6.  Polymyxin: Alternative Mechanisms of Action and Resistance.

Authors:  Michael J Trimble; Patrik Mlynárčik; Milan Kolář; Robert E W Hancock
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

7.  Multidrug Adaptive Resistance of Pseudomonas aeruginosa Swarming Cells.

Authors:  Shannon R Coleman; Travis Blimkie; Reza Falsafi; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.

Authors:  Alina D Gutu; Nicole Sgambati; Pnina Strasbourger; Mark K Brannon; Michael A Jacobs; Eric Haugen; Rajinder K Kaul; Helle Krogh Johansen; Niels Høiby; Samuel M Moskowitz
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 10.  Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.

Authors:  Tony Velkov; Kade D Roberts; Roger L Nation; Philip E Thompson; Jian Li
Journal:  Future Microbiol       Date:  2013-06       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.